Bristol Myers Squibb (BMY) Change in Account Payables (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Change in Account Payables data on file, last reported at $409.0 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at $409.0 million, up 581.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $492.0 million (up 344.78% YoY), and the FY2025 annual result was -$2.0 million, down 101.09% from the prior year.
• Change in Account Payables climbed to $409.0 million in Q1 2026 per BMY's latest filing, from -$90.0 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $517.0 million in Q4 2024 and troughed at -$374.0 million in Q3 2024.
• A 5-year average of $52.8 million and a median of $13.0 million in 2025 frame the typical range for Change in Account Payables.
• On a YoY basis, Change in Account Payables climbed as much as 713.04% in 2023 and fell as far as 768.42% in 2023.
• A 5-year view of Change in Account Payables shows it stood at $405.0 million in 2022, then increased by 9.63% to $444.0 million in 2023, then rose by 16.44% to $517.0 million in 2024, then tumbled by 117.41% to -$90.0 million in 2025, then soared by 554.44% to $409.0 million in 2026.
• Business Quant data shows BMY's Change in Account Payables at $409.0 million in Q1 2026, -$90.0 million in Q4 2025, and $160.0 million in Q3 2025.